ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read More
    Services
    Adaptive TrialsClinical Research ServicesConsultingEarly PhaseFunctional Services ProvisionLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceValue Access Outcomes
    Site and patient identification, enrolment and engagement.
    Site & Patient Solutions

    Site and patient identification, enrolment and engagement.

    Integrated services that cover planning, management, execution and analysis.
    Clinical Research Services

    Integrated services that cover planning, management, execution and analysis.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read More
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    The new EU medical and in vitro diagnostic device regulations go into effect at the start of 2020. Are you ready?
    EU MDR/IVDR Regulations

    The new EU medical and in vitro diagnostic device regulations go into effect at the start of 2020. Are you ready?

    Strategies and recommendations to achieve optimal market access.
    Making sense of the Biosimilars market

    Strategies and recommendations to achieve optimal market access.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read More
    Therapeutics
    CardiovascularCentral Nervous SystemEndocrine & Metabolic DisordersGenomicsInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOphthalmologyRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
    Oncology

    ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.

    ICON has recently led the development of 14 vaccines resulting in FDA/EMA approvals.
    Vaccines

    ICON has recently led the development of 14 vaccines resulting in FDA/EMA approvals.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read More
    Innovation
    FIRECRESTIntel Pharma Analytics PlatformDrug Safety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGE Medical Imaging TechnologyNONMEM ICONIKPDx-POPIMRAPubsHub
    Using data to design, simulate, and analyse adaptive clinical trials with ease.
    ADDPLAN®

    Using data to design, simulate, and analyse adaptive clinical trials with ease.

    Connecting patients with the right trial in the right location.
    Patient Engagement Portal

    Connecting patients with the right trial in the right location.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read More
    Insights
    Digital Disruption Patient CentricityTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Remote monitoring and leveraging wearable devices and sensors in clinical trials.
    mHealth & Wearables

    Remote monitoring and leveraging wearable devices and sensors in clinical trials.

    Reduce post market study costs with Real World Data.
    Real World Data

    Reduce post market study costs with Real World Data.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read More
    News & Events
    Press ReleasesIn the NewsEventsMediakitSocial MediaAwards
    7 - 10 December, 2019
    ASH Annual Meeting

    7 - 10 December, 2019

    Visit the Webinar Channel
    On-Demand Webinars

    Visit the Webinar Channel

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read More
    About ICON
    Company HistoryICON in Asia PacificICON in Latin AmericaLeadership
    We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
    Quality

    We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.

    Partners Making a Difference.
    ICON and You

    Partners Making a Difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • EN | 日本語
  1. Home
  2. Insights
  3. Blog

Blog

  • 03 December 2019

    Healthcare Resource Use and Costs in AML Patients Undergoing Stem Cell Transplantation

    ISPOR EU 2019 WINNER - Best General Poster Research Presentations: Health Care Use and Costs in Acute Myeloid Leukaemia (AML) Patients Undergoing Stem Cell Transplantation.

  • 27 November 2019

    Innovation in Oncology Drug Development

    Significant progress has been made in our understanding of the molecular lesions responsible for tumor cells to exhibit uncontrolled growth.

  • 22 November 2019

    Top Five Digital Technologies Set to Transform Pharma R&D

    The current wave of emerging digital technologies offers an opportunity to significantly disrupt pharma business operating models in a variety of ways.

  • 19 November 2019

    The Impact of Digital Technology on Patient Engagement in Clinical Trials

    The use of digital technology in clinical trials is creating more convenient, engaging and innovative treatments for patients

  • 15 November 2019

    Payers Report that ICER Analyses Increasingly Guide US Price Negotiations

    According to a survey conducted by ICON in July 2019, prescription drug cost effectiveness analyses by the Institute for Clinical and Economic Review (ICER) are playing an increasingly important role in price negotiations.

  • 14 November 2019

    Four Challenges to Successful Rare Disease Drug Development

    Overcoming these challenges can greatly improve chances for a successful rare or orphan drug trial.

  • 01 November 2019

    Harnessing Big Data: The raw material of digital transformation

    The integration and mastery of digital technologies is becoming essential to improve the efficiency of clinical trial operations.

  • 31 October 2019

    Challenges and Advances in NASH Clinical Trials

    NASH is massively under-diagnosed, partly because it is a silent disease and partly because definitive diagnosis is by histopathology of a liver biopsy with associated risks.

  • 29 October 2019

    MDR / IVDR Regulatory Roundup

    Less than one year remains before the European Union’s new Medical Device Regulation (MDR) goes into effect on May 26, 2020, and only about a fourth of medical device companies plan to be fully complaint,

  • 25 October 2019

    Value-Based Healthcare: Matching who benefits with who pays

    The key to success in the medical device market is to ensure that value benefits align across stakeholders, especially with the payers.

  • 24 October 2019

    Real-World Evidence Generated through Hybrid Studies

    Hybrid CSS-MCR studies can be advantageous in generating real world evidence to answer epidemiology questions efficiently and effectively.

  • 18 October 2019

    RWE and the Clinical Research Landscape

    A new era is emerging in which clinical practice and clinical research inform one another through RWE.

  • 10 October 2019

    Pharma ROI Restoration

    Using Big Data and AI to return pharma productivity to sustainable levels.

  • 01 October 2019

    The Rare Disease Revolution

    Emerging research approaches and real-world evidence are fulfilling the needs of rare disease patients with increased speed.

  • 30 September 2019

    Real World Evidence: The Evolving Views of Regulators and Payers

    RWE is being used to provide a more comprehensive data set for regulators’ and payers’ use in approval and reimbursement decisions.

  • 19 September 2019

    Can AI improve R&D productivity enough to restore ROI to sustainable levels?

    According to an ICON survey, artificial intelligence (AI) was considered the digital technology with the most potential to improve R&D productivity

  • 16 September 2019

    Key Considerations for Disease-Modifying Parkinson’s Disease Trials

    Taking into consideration the lessons learned from Alzheimer’s disease studies could benefit the design of neuro-protective studies.

  • 12 September 2019

    Oncology Clinical Trials in Asia Pacific

    The size and significance of the APAC market make clinical trials, on the cutting edge of oncology development, an attractive investment.

  • 09 September 2019

    The importance of the patient voice in the rare disease market

    Orphan drugs, by nature, remain commercially underdeveloped, and as demand in the market increases, patients in clinical trials need to be considered.

  • 09 September 2019

    Adoptive Cellular Transfer (ACT): Novel Cancer Trials Demand That Participating Sites Act Differently

    Sites participating in ACT trials need to be prepared with regulatory intelligence, scalable logistics, adequate resources and dedicated data management teams.

In this section
In this section
  • Digital Disruption
    • AI and Clinical Trials
      • Impact of AI on Outcomes Based Contracting
    • Addressing Cybersecurity for Your Medical Device
    • Digital disruption in biopharma
    • Disruptive Innovation
    • mHealth & Wearables
      • Bring Your Own Device
      • Transforming Medical Device Development with mHealth
    • Personalising Digital Health
    • Real World Data
      • Harnessing Technology to Maximise Real World Evidence Value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
  • Patient Centricity
    • Charting the Managed Access Program Landscape
    • Developing Nurse-Centric Medical Communications
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
  • Transforming Trials
    • Adaptive Clinical Trials
      • How to Avoid 3 Key Sources of Error in Adaptive Trials
      • Adaptive Design: The Faster Path to Market
      • How to Gain the FLEX ADVANTAGE
    • CRO Partnership Strategies
    • Improving Pharma R&D Efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Risk Based Monitoring
    • Transforming the R&D Model to Sustain Growth
  • Value Based Healthcare
    • Cardiovascular Medical Devices
    • Global Outcomes Benchmarking
    • Making Sense of the Biosimilars Market
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • The Role of ICER as an HTA Organisation
  • Blog
  • Videos
  • Webinar Channel
  • mHealth & Wearables
    • Bring Your Own Device
    • Transforming Medical Device Development with mHealth
  • Real World Data
    • Harnessing Technology to Maximise Real World Evidence Value
    • Meeting Evidentiary Needs with EHRs
    • Post-Market Surveillance for Medical Devices

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What's happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
ICON For
  • Investigators
  • Mediakit
  • Volunteers
  • Investors
  • Jobs & Careers
News & Events
  • Press Releases
  • Events
  • ICON on Social Media
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2019 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies

Connect with us

Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media